Catalyst Wire Dossier Catalyst Wire Dossier

CMVpp65-specific T cells

CMV pp65-specific cytotoxic T lymphocytes · Memorial Sloan Kettering Cancer Center
Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for CMVpp65-specific T cells, covering 2020-12-16 to 2024-10-17. Get the full timeline:

Most recent: Clinical Trial Update: Trial of Third Party Donor Derived CMVpp65 Specific T-cells for The Treatment of CMV Infection or Persistent CMV Viremia After Allogeneic Hematopoietic Stem Cell Transplantation [Phase 2]

See pricing